Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05044195 · ClinicalTrials.gov registry record · Phase 3

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

A Phase 3 study of Influenza, Human, sponsored by Seqirus.

Completed
Registry status
Phase 3
Development phase
2,044
Enrollment target
20
Study locations

NCT05044195 is a Phase 3 study of Influenza, Human that has completed, run by Seqirus. The registered enrollment target is 2,044 participants, below the 16,110-participant average among 18 other Influenza, Human trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05044195, a Phase 3 study of Influenza, Human, has completed, sponsored by Seqirus.

COMPLETED
Registry status
Phase 3
Development phase
2,044 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.

Conditions Studied

Influenza, Human

Interventions

  • BIOLOGICAL aQIV
  • BIOLOGICAL Comparator QIV

Study Locations (20)

Other

  • 23302 Vee Family Doctors Centre - Paide
  • 23301 Innomedica OÜ - Outpatient - Tallinn
  • 23303 Al Mare Perearstikeskus OÜ - Tallinn
  • 23304 Merelahe Family Doctors Centre - Tallinn
  • 23306 Center for Clinical and Basic Research - Tallinn
  • 23305 Clinical Research Center - Vaccine Trials - Tartu
  • 27602 Klinische Forschung Berlin - Berlin
  • 27603 Emovis GmbH - Berlin

Nebraska

  • 84009 Meridian Clinical Research - Lincoln
  • 84002 Meridian Clinical Research - Norfolk
  • 84004 Meridian Clinical Research - Omaha

Florida

  • 84005 JEM Research Institute - Atlantis
  • 84010 Headlands Research Orlando - Orlando

New York

  • 84008 United Medical Associates - Binghamton
  • 84011 Meridian Clinical Research - Endwell

Alabama

  • 84013 Coastal Clinical Research, Inc. - Mobile

Arizona

  • 84007 Alliance for Multispecialty Research - Tempe

Georgia

  • 84001 Meridian Clinical Research - Savannah

Iowa

  • 84003 Meridian Clinical Research - Sioux City

Trial Details

FieldValue
Enrollment Target 2,044 participants
Start Date 2021-09-30
Est. Completion 2022-09-09
Phase Phase 3

Sponsor

Seqirus

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05044195

The ClinicalTrials.gov registry entry for NCT05044195 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,044 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,110-participant average among 18 other Influenza, Human trials with a reported enrollment target (87% lower). The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 2 interventions - of which aQIV is the first listed.

NCT05044195 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Nebraska, Florida.

Frequently Asked Questions

What is clinical trial NCT05044195 about?

NCT05044195 is a clinical study titled "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age". This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.

What is the current status of trial NCT05044195?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,044 participants. The study started on 2021-09-30. Estimated completion is 2022-09-09.

What conditions does trial NCT05044195 study?

This clinical trial studies the following conditions: Influenza, Human.

What interventions are being tested in trial NCT05044195?

The interventions under investigation include: aQIV (BIOLOGICAL), Comparator QIV (BIOLOGICAL).

Who is sponsoring clinical trial NCT05044195?

This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05044195 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza, Human

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Influenza, Human

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.